Skip to main content

REVIEW article

Front. Nutr.
Sec. Clinical Nutrition
Volume 11 - 2024 | doi: 10.3389/fnut.2024.1501817
This article is part of the Research Topic Gluten-Related Disorders: Pathogenesis, Diagnosis, and Treatment View all 8 articles

BEYOND GLUTEN-FREE DIET: A CRITICAL PERSPECTIVE ON PHASE 2 TRIALS ON NON-DIETARY PHARMACOLOGICAL THERAPIES FOR COELIAC DISEASE Short title: alternative and pharmacologic therapies in CeD

Provisionally accepted
Davide Scalvini Davide Scalvini 1Chiara Scarcella Chiara Scarcella 2Giulia Mantica Giulia Mantica 1Erica Bartolotta Erica Bartolotta 1Stiliano Maimaris Stiliano Maimaris 1Erica Fazzino Erica Fazzino 1Federico Biagi Federico Biagi 1ANNALISA SCHIEPATTI ANNALISA SCHIEPATTI 1,2*
  • 1 Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Lombardy, Italy
  • 2 IRCCS Fondazione Salvatore Maugeri, Pavia, Lombardy, Italy

The final, formatted version of the article will be published soon.

    Coeliac disease is an immune-mediated chronic enteropathy, with a prevalence of around 1% in the general population and occurring in genetically susceptible individuals after the ingestion of gluten proteins present in wheat, rye and barley. Currently, a strict lifelong gluten-free diet is the cornerstone of treatment of coeliac disease. However, maintaining strict dietary adherence is challenging for many patients, due to the high costs, the highly restrictive nature of the diet and the impact on patients' quality of life. Moreover, a tiny minority of coeliac patients can develop pre-malignant/malignant complications of coeliac disease, a group of conditions, that despite being rare, are still burdened by a poor prognosis due to the lack of effective therapies. Therefore, the development of pharmacological treatments as an alternative to or supportive of a gluten-free diet is still an unmet need. The identification of new pathogenetic targets in the last years has enabled the development of several candidates molecules, many of which have been investigated in phase 2/3 clinical trials.In this narrative review we aim to summarize the investigational therapies that have been evaluated in phase 2/3 trials and provide a critical overview on the latest advances in this field.

    Keywords: coeliac disease, gluten-free diet, Alternative Therapies, Pharmacologic therapies, persistent symptom

    Received: 25 Sep 2024; Accepted: 06 Dec 2024.

    Copyright: © 2024 Scalvini, Scarcella, Mantica, Bartolotta, Maimaris, Fazzino, Biagi and SCHIEPATTI. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: ANNALISA SCHIEPATTI, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, 27100, Lombardy, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.